サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1571390

ラテンアメリカの化学発光免疫測定法の市場規模・予測、世界・地域別シェア、動向、成長機会分析レポート：用途別、エンドユーザー別、国別

Latin America Chemiluminescence Immunoassay Market Size and Forecast, Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application, End User, and Country

出版日
ページ情報
英文 88 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ラテンアメリカの化学発光免疫測定法の市場規模・予測、世界・地域別シェア、動向、成長機会分析レポート：用途別、エンドユーザー別、国別
出版日: 2024年10月08日
発行: The Insight Partners
ページ情報: 英文 88 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ラテンアメリカの化学発光免疫測定法（CLIA）市場規模は、2023年の4億9,767万米ドルから成長し、2031年には9億5,512万米ドルに達すると予測されており、2023～2031年のCAGRは8.6%と予測されています。

脚用圧迫ラップは、リンパ浮腫の症状を管理・緩和するために設計されています。これらのラップは、脚の患部に制御された圧力を加えることにより、リンパ液の流れを助け、腫れを減少させる。従来の圧迫ストッキングに比べ、圧迫ラップは調節可能なため、ストッキングを着用するのが困難な人や、浮腫のレベルが変動する人に理想的な選択肢です。調節可能な圧迫ラップはかなり安価で、潰瘍治癒に効果的です。したがって、調節可能な圧迫ラップは、静脈性下腿潰瘍の治療において、非弾性包帯に代わる強力で自己適用可能な費用効果の高い選択肢です。ラテンアメリカの化学発光免疫測定法市場規模の拡大には、静脈疾患の増加やリンパ浮腫につながるがんの発生率の増加が寄与しています。しかし、リンパ浮腫、慢性静脈不全、末梢性浮腫、静脈うっ滞性潰瘍、静脈瘤などの病態は、薬物療法や外科的処置、特に低侵襲処置でも治療可能であるため、代替治療が可能であることがラテンアメリカの化学発光免疫測定法市場の成長を妨げています。上記の疾患の治療に用いられるその他の治療法には、泡沫硬化療法、レーザー治療、外来静脈瘤切除術、高周波またはレーザーエネルギーを用いるカテーテル支援手技などがあります。下肢深部静脈の血栓予防には、間欠的空気圧迫装置などの技術も用いられます。これは、自然な筋肉の収縮を模倣し、静脈の還流を助ける装置を用いるものです。このように、上記の疾患の治療には圧迫衣、装置、治療法などの代替治療が利用可能であることが、ラテンアメリカの化学発光免疫測定法市場の成長を妨げています。

用途別洞察

ラテンアメリカの化学発光免疫測定法市場は、用途別に腫瘍、不妊、内分泌、循環器、感染症、糖尿病、その他に区分されます。2023年のラテンアメリカ化学発光免疫測定法市場シェアは、がん分野が最大でした。Lancet誌によると、2023年現在、ラテンアメリカ・カリブ海地域（LAC）では、年間～150万人の新規がん患者と～70万人のがん関連死が記録されています。世界保健機関（WHO）によると、ブラジルではがんが死因の第2位にランクされており、2018年には227,920人が死亡しています。また、がんによる年齢調整死亡率は、男性で10万人当たり111人、女性で10万人当たり95人であると報告しています。Revista Brasileira de Cancerologiaによると、2023年にはブラジルで704,000人近くの新規がん症例が報告されています。例えば、EDI Human Chromogranin A CLIA Kitは、ECL100またはECL25免疫測定法・アナライザーを用いた血清中のヒト・クロモグラニンA（CgA）レベルの定量的検出に適応されます。この検査は、褐色細胞腫および神経内分泌腫瘍（カルチノイドなど）の患者を検出する補助として使用できます。

また、不妊治療分野は2023年から2031年にかけて最も高いCAGRを記録すると予想されています。米国国立衛生研究所（NIH）によると、16カ国の～188のセンターが2020年に87,732人の女性が初経を迎えたと報告し、ラテンアメリカでは12,778人の出産と14,405人の生児出生が記録されました。ラテンアメリカ経済委員会（Comision Economica para America Latina y el Caribe）によると、2015年に置換水準を下回ったラテンアメリカの合計特殊出生率（TFR）は、2022年には女性1人当たりの出生数が1.85となり、さらに2100年には1.68まで低下すると予測されています。また、平均出産年齢も上昇しています。Biopandaプロラクチン化学発光免疫測定法キットは、ヒト血清中のプロラクチンを定量的に測定する手段を提供します。化学発光免疫測定法は、高い相関性や実用性の向上などの要因により、血清プロゲステロンの測定においてラジオ免疫測定法に代わって現在の標準となっています。このように、上記の要因がラテンアメリカの化学発光免疫測定法市場の成長を支えています。

エンドユーザーに基づく洞察

ラテンアメリカの化学発光免疫測定法市場は、エンドユーザー別に病院、血液バンク、臨床検査室、製薬・バイオテクノロジー企業、その他に区分されます。病院セグメントは2023年にラテンアメリカの化学発光免疫測定法市場で最大のシェアを占め、臨床検査室セグメントは2023-2031年に市場で最も高いCAGRを記録すると予測されています。免疫診断検査は、臨床微生物学研究室、病理学研究室、血清学研究室、病理組織学・血液学部門、臨床生化学研究室、病棟など、病院のさまざまな部門で実施されています。いくつかの免疫診断装置は迅速な結果を提供するが、複雑な検査の場合、サンプルは専門の検査室に送られます。病院環境におけるポイントオブケア（POC）免疫測定検査製品に対する需要の高まりは、CLIA市場に利益をもたらしています。現在、CLIA検査は腫瘍マーカーの検出、感染症、内分泌疾患、糖尿病などの診断に使用されています。一つの自動化されたシステムでこのような多様な応用が可能であるため、CLIAシステムは病院で重要な応用可能性を見出しています。

しかし、国内または国際的な規制要件に準拠して構築された診断検査室は、病院、診療所、在宅医療施設などに診断サービスを提供するためにCLIAベースのキットや機器を使用しています。ラテンアメリカにおける慢性疾患や感染症の急増、免疫診断手順のアウトソーシングが、診断ラボ分野におけるラテンアメリカ化学発光免疫測定法市場の成長を支える要因となっています。

The Global Cancer Observatory、OECD、National Center for Biotechnology Informationなどは、ラテンアメリカの化学発光免疫測定法市場レポート作成時に参照した一次情報および二次情報です。

目次

第1章 イントロダクション

第2章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第3章 ラテンアメリカ化学発光免疫測定法市場情勢

  • 市場概要
  • PEST分析

第4章 ラテンアメリカ化学発光免疫測定法市場- 主要市場力学

  • ラテンアメリカ化学発光免疫測定法市場- 主要市場力学
  • 市場促進要因
    • 感染症罹患率の上昇
    • ポイントオブケア診断の利用拡大
  • 市場抑制要因
    • 不十分な償還
  • 市場機会
    • 研究開発への注力の高まり
  • 今後の動向
    • 技術の進歩
  • 促進要因と抑制要因の影響

第5章 ラテンアメリカの化学発光免疫測定法市場分析

  • 化学発光免疫測定法市場
    • 化学発光免疫測定法市場-2031年までの収益と予測

第6章 ラテンアメリカの化学発光免疫測定法市場：用途別

  • 腫瘍学
  • 不妊治療
  • 内分泌学
  • 心臓病学
  • 感染症
  • 糖尿病
  • その他

第7章 ラテンアメリカの化学発光免疫測定法市場：エンドユーザー別

  • 病院
  • 血液バンク
  • 臨床研究所
  • 製薬・バイオテクノロジー企業
  • その他

第8章 ラテンアメリカの化学発光免疫測定法市場：地域別

  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
    • チリ
    • メキシコ
    • その他ラテンアメリカ

第9章 企業プロファイル

  • Sysmex Corp
  • Shenzhen Mindray Bio-Medical Electronics Co Ltd
  • Bio-Rad Laboratories Inc
  • Merck KGaA
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Hoffmann-La Roche Ltd
  • DiaSorin SpA
  • Siemens Healthineers AG
  • Getein Biotech Inc.

第10章 付録

図表

List Of Tables

  • Table 1. Latin America Chemiluminescence Immunoassay (CLIA) Market Segmentation
  • Table 2. Latin America Chemiluminescence Immunoassay (CLIA) Market- Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 3. Latin America Chemiluminescence Immunoassay (CLIA) Market- Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 4. Latin America: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 5. Latin America: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 6. Brazil: Chemiluminescence Immunoassay (CLIA) Market- Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 7. Brazil: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 8. Argentina: Chemiluminescence Immunoassay (CLIA) Market- Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 9. Argentina: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 10. Chile: Chemiluminescence Immunoassay (CLIA) Market- Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 11. Chile: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 12. Mexico: Chemiluminescence Immunoassay (CLIA) Market- Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 13. Mexico: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 14. Rest of Latin America: Chemiluminescence Immunoassay (CLIA) Market- Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 15. Rest of Latin America: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 16. Glossary of Terms, Latin America Chemiluminescence Immunoassay (CLIA) Market

List Of Figures

  • Figure 1. Analysis
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Chemiluminescence Immunoassay (CLIA): Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 4. Latin America Chemiluminescence Immunoassay (CLIA) Market Share (%) - by Application (2024 and 2031)
  • Figure 5. Oncology: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 6. Fertility: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Endocrinology: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Cardiology: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Infectious Diseases: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Diabetes: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Others: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Latin America Chemiluminescence Immunoassay (CLIA) Market Share (%) - by End User (2024 and 2031)
  • Figure 13. Hospitals: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Blood Banks: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Clinical Laboratories: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Pharmaceutical & Biotech Companies: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Others: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Latin America Chemiluminescence Immunoassay (CLIA) Market Breakdown by Countries, 2023 and 2031 (%)
  • Figure 19. Latin America: Latin America Chemiluminescence Immunoassay (CLIA), by Key Country - Revenue (2023) (USD Million)
  • Figure 20. Latin America: Latin America Chemiluminescence Immunoassay (CLIA)- Revenue and Forecast to 2031(US$ Million)
  • Figure 21. Brazil: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 22. Argentina: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 23. Chile: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 24. Mexico: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 25. Rest of Latin America: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031(US$ Million)
目次
Product Code: TIPRE00039333

The Latin America chemiluminescence immunoassay market size is expected to grow from US$ 497.67 million in 2023 and is projected to reach US$ 955.12 million by 2031; it is expected to register a CAGR of 8.6% during 2023-2031.

Compression wraps for legs are designed to manage and alleviate the symptoms of lymphedema. These wraps help with the flow of lymph fluids and decrease swelling by applying controlled pressure to the affected areas of the leg. Compared to traditional compression stockings, compression wraps are adjustable, making them an ideal choice for individuals having difficulty putting on stockings or are experiencing fluctuating levels of edema. Adjustable compression wraps are considerably less expensive and more effective in achieving ulcer healing. Therefore, adjustable compression wraps are a powerful, self-applicable, and cost-effective alternative to inelastic bandages in treating venous leg ulcers. The increasing occurrence of venous conditions and the growing incidence of cancer leading to lymphedema are noteworthy factors contributing to the expansion of the Latin America chemiluminescence immunoassay market size. However, the availability of alternate treatments hinders the Latin America chemiluminescence immunoassay market growth as conditions such as lymphedema, chronic venous insufficiency, peripheral edema, venous stasis ulcers, and varicose veins can also be treated via medication and surgical procedures, especially minimally invasive procedures. Other treatment procedures used to treat the abovementioned conditions include foam sclerotherapy, laser treatment, ambulatory phlebectomy, and catheter-assisted procedures that use radiofrequency or laser energy. Techniques such as intermittent pneumatic compression devices are also used to prevent blood clots in the deep veins of the legs. It employs a device to mimic natural muscle contractions, aiding in venous return. Thus, the availability of alternative treatments, such as compression garments, devices, and therapies for the treatment of the abovementioned conditions, hampers the growth of the Latin America chemiluminescence immunoassay market.

Application-Based Insights

Based on application, the Latin America chemiluminescence immunoassay market is segmented into oncology, fertility, endocrinology, cardiology, infectious diseases, diabetes, and others. The oncology segment held the largest Latin America chemiluminescence immunoassay market share in 2023. According to the Lancet, ~1.5 million new cancer cases and ~700,000 cancer-related deaths are annually recorded in Latin America and the Caribbean (LAC) region as of 2023. According to the World Health Organization, in Brazil, cancer is ranked as the second leading cause of death, resulting in 227,920 deaths in 2018. It also reports that the age-adjusted death rate due to cancer is 111 per 100,000 for men and 95 per 100,000 for women. According to the Revista Brasileira de Cancerologia, nearly 704,000 new cancer cases were reported in Brazil in 2023. For instance, the EDI Human Chromogranin A CLIA Kit is indicated for the quantitative detection of human chromogranin A (CgA) levels in serum using the ECL100 or ECL25 immunoassay analyzer. This test may be used as an aid to detect patients with pheochromocytoma and neuroendocrine tumors (such as carcinoids, etc.).

In addition, the Fertility segment is expected to register the highest CAGR from 2023 to 2031. According to the National Institutes of Health (NIH), ~188 centers in 16 countries reported 87,732 females had their first menstrual cycles in 2020, and 12,778 childbirths and 14,405 live births were recorded in Latin America. According to the Comision Economica para America Latina y el Caribe, the total fertility rate (TFR) of Latin America, which fell below replacement level in 2015, was estimated at 1.85 live births per woman in 2022, with a further projection to drop to 1.68 by 2100. There has also been an increase in the average age of fertility. The Biopanda Prolactin chemiluminescence immunoassay test kit provides a means for the quantitative determination of prolactin in human serum. Chemiluminescent immunoassay has replaced radioimmunoassay in the measurement of serum progesterone as a current standard owing to factors such as high correlation and increased practicality. Thus, the factors mentioned above support Latin America chemiluminescence immunoassay market growth.

End User-Based Insights

Based on end user, the Latin America chemiluminescence immunoassay market is segmented into hospitals, blood banks, clinical laboratories, pharmaceutical & biotech companies, and others. The hospitals segment held the largest Latin America chemiluminescence immunoassay market share in 2023 and clinical laboratories segment is expected to register the highest CAGR in the market during 2023-2031. Immunodiagnostics tests are performed in different hospital departments, including clinical microbiology labs, pathological labs, serological labs, histopathology and hematology sections, clinical biochemistry labs, and hospital wards. Some A few immunodiagnostic instruments provide quick results, while samples are sent to specialized laboratories in the case of complex tests. The rising demand for point-of-care (POC) immunoassay testing products in hospital settings benefits the CLIA market. At present, CLIA tests are employed to detect tumor markers and diagnose infectious diseases, endocrine disorders, diabetes, and so on. With such varied applications in one automated system, CLIA systems find significant applicability in hospitals.

However, Diagnostic laboratories, built in adherence to domestic or international regulatory requirements, use CLIA-based kits and instruments for providing diagnostics services to hospitals, clinics, at-home care setups, etc. The surging prevalence of chronic and infectious diseases in Latin America, and the practice of outsourcing immunodiagnostics procedures are the factors supporting the Latin America chemiluminescence immunoassay market growth in the diagnostic laboratories segment.

The Global Cancer Observatory, OECD, and National Center for Biotechnology Information are among the primary and secondary sources referred to while preparing the Latin America chemiluminescence immunoassay market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Research Methodology

  • 2.1 Coverage
  • 2.2 Secondary Research
  • 2.3 Primary Research

3. Latin America Chemiluminescence Immunoassay (CLIA) Market Landscape

  • 3.1 Market Overview
  • 3.2 PEST Analysis

4. Latin America Chemiluminescence Immunoassay (CLIA) Market - Key Market Dynamics

  • 4.1 Latin America Chemiluminescence Immunoassay Market - Key Market Dynamics
  • 4.2 Market Drivers:
    • 4.2.1 Rising Incidence of Infectious Diseases
    • 4.2.2 Growing Use of Point-of-Care Diagnostics
  • 4.3 Market Restraints
    • 4.3.1 Inadequate Reimbursement
  • 4.4 Market Opportunities
    • 4.4.1 Increasing Focus on R&D
  • 4.5 Future Trends
    • 4.5.1 Technological Advancement
  • 4.1 Impact of Drivers and Restraints:

5. Latin America Chemiluminescence Immunoassay (CLIA) Market Analysis

  • 5.1 Chemiluminescence Immunoassay (CLIA) Market
    • 5.1.1 Overview
    • 5.1.2 Chemiluminescence Immunoassay (CLIA): Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)

6. Latin America Chemiluminescence Immunoassay (CLIA) Market Analysis - by Application

  • 6.1 Oncology
    • 6.1.1 Overview
    • 6.1.2 Oncology: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.2 Fertility
    • 6.2.1 Overview
    • 6.2.2 Fertility: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Endocrinology
    • 6.3.1 Overview
    • 6.3.2 Endocrinology: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Cardiology
    • 6.4.1 Overview
    • 6.4.2 Cardiology: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.5 Infectious Diseases
    • 6.5.1 Overview
    • 6.5.2 Infectious Diseases: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.6 Diabetes
    • 6.6.1 Overview
    • 6.6.2 Diabetes: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.7 Others
    • 6.7.1 Overview
    • 6.7.2 Others: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)

7. Latin America Chemiluminescence Immunoassay (CLIA) Market Analysis - by End User

  • 7.1 Hospitals
    • 7.1.1 Overview
    • 7.1.2 Hospitals: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Blood Banks
    • 7.2.1 Overview
    • 7.2.2 Blood Banks: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Clinical Laboratories
    • 7.3.1 Overview
    • 7.3.2 Clinical Laboratories: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Pharmaceutical & Biotech Companies
    • 7.4.1 Overview
    • 7.4.2 Pharmaceutical & Biotech Companies: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Others
    • 7.5.1 Overview
    • 7.5.2 Others: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)

8. Latin America Chemiluminescence Immunoassay (CLIA) Market - Regional Analysis

  • 8.1 Overview
  • 8.2 Latin America
    • 8.2.1 Latin America Chemiluminescence Immunoassay (CLIA) Market Overview
    • 8.2.2 Latin America: Latin America Chemiluminescence Immunoassay (CLIA)- Revenue and Forecast to 2031 (US$ Million)
      • 8.2.2.1 Latin America: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast Analysis - by Application
      • 8.2.2.2 Latin America: Latin America Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast Analysis - by End User
      • 8.2.2.3 Brazil: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
        • 8.2.2.3.1 Brazil: Chemiluminescence Immunoassay (CLIA) Market Breakdown, by Application
        • 8.2.2.3.2 Brazil: Chemiluminescence Immunoassay (CLIA) Market Breakdown, by End User
      • 8.2.2.4 Argentina: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
        • 8.2.2.4.1 Argentina: Chemiluminescence Immunoassay (CLIA) Market Breakdown, by Application
        • 8.2.2.4.2 Argentina: Chemiluminescence Immunoassay (CLIA) Market Breakdown, by End User
      • 8.2.2.5 Chile: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
        • 8.2.2.5.1 Chile: Chemiluminescence Immunoassay (CLIA) Market Breakdown, by Application
        • 8.2.2.5.2 Chile: Chemiluminescence Immunoassay (CLIA) Market Breakdown, by End User
      • 8.2.2.6 Mexico: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
        • 8.2.2.6.1 Mexico: Chemiluminescence Immunoassay (CLIA) Market Breakdown, by Application
        • 8.2.2.6.2 Mexico: Chemiluminescence Immunoassay (CLIA) Market Breakdown, by End User
      • 8.2.2.7 Rest of Latin America: Chemiluminescence Immunoassay (CLIA) Market - Revenue and Forecast to 2031 (US$ Million)
        • 8.2.2.7.1 Rest of Latin America: Chemiluminescence Immunoassay (CLIA) Market Breakdown, by Application
        • 8.2.2.7.2 Rest of Latin America: Chemiluminescence Immunoassay (CLIA) Market Breakdown, by End User

9. Company Profiles

  • 9.1 Sysmex Corp
    • 9.1.1 Key Facts
    • 9.1.2 Business Description
    • 9.1.3 Products and Services
    • 9.1.4 Financial Overview
    • 9.1.5 SWOT Analysis
    • 9.1.6 Key Developments
  • 9.2 Shenzhen Mindray Bio-Medical Electronics Co Ltd
    • 9.2.1 Key Facts
    • 9.2.2 Business Description
    • 9.2.3 Products and Services
    • 9.2.4 Financial Overview
    • 9.2.5 SWOT Analysis
    • 9.2.6 Key Developments
  • 9.3 Bio-Rad Laboratories Inc
    • 9.3.1 Key Facts
    • 9.3.2 Business Description
    • 9.3.3 Products and Services
    • 9.3.4 Financial Overview
    • 9.3.5 SWOT Analysis
    • 9.3.6 Key Developments
  • 9.4 Merck KGaA
    • 9.4.1 Key Facts
    • 9.4.2 Business Description
    • 9.4.3 Products and Services
    • 9.4.4 Financial Overview
    • 9.4.5 SWOT Analysis
    • 9.4.6 Key Developments
  • 9.5 Abbott Laboratories
    • 9.5.1 Key Facts
    • 9.5.2 Business Description
    • 9.5.3 Products and Services
    • 9.5.4 Financial Overview
    • 9.5.5 SWOT Analysis
    • 9.5.6 Key Developments
  • 9.6 Thermo Fisher Scientific Inc.
    • 9.6.1 Key Facts
    • 9.6.2 Business Description
    • 9.6.3 Products and Services
    • 9.6.4 Financial Overview
    • 9.6.5 SWOT Analysis
    • 9.6.6 Key Developments
  • 9.7 Hoffmann-La Roche Ltd
    • 9.7.1 Key Facts
    • 9.7.2 Business Description
    • 9.7.3 Products and Services
    • 9.7.4 Financial Overview
    • 9.7.5 SWOT Analysis
    • 9.7.6 Key Developments
  • 9.8 DiaSorin SpA
    • 9.8.1 Key Facts
    • 9.8.2 Business Description
    • 9.8.3 Products and Services
    • 9.8.4 Financial Overview
    • 9.8.5 SWOT Analysis
    • 9.8.6 Key Developments
  • 9.9 Siemens Healthineers AG
    • 9.9.1 Key Facts
    • 9.9.2 Business Description
    • 9.9.3 Products and Services
    • 9.9.4 Financial Overview
    • 9.9.5 SWOT Analysis
    • 9.9.6 Key Developments
  • 9.10 Getein Biotech Inc.
    • 9.10.1 Key Facts
    • 9.10.2 Business Description
    • 9.10.3 Products and Services
    • 9.10.4 Financial Overview
    • 9.10.5 SWOT Analysis
    • 9.10.6 Key Developments

10. Appendix

  • 10.1 About The Insight Partners
  • 10.2 Glossary of Terms